Equatorial Guinea
Tuberculosis profile
| High HIV burden |
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.067 (0.021–0.11) 8.8 (2.8–15)
Mortality (HIV+TB only) 0.041 (0.026–0.06) 5.4 (3.4–7.9)
Prevalence  (includes HIV+TB) 1.2 (0.52–2) 153 (68–270)
Incidence  (includes HIV+TB) 1.1 (1–1.2) 144 (132–155)
Incidence (HIV+TB only) 0.27 (0.24–0.29) 36 (32–39)
Case detection, all forms (%)        
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.9–2.6) 13 (11–15)
MDR-TB cases among notified pulmonary
TB cases
  (–)   (–)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed      
Pulmonary, clinically diagnosed      
Extrapulmonary      
       
Total new and relapse      
Previously treated, excluding relapses      
Total cases notified      
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012  
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population)  
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available?  
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-04 Data: www.who.int/tb/data